Francesco Felicett, E. Brignardello, H. Santen, F. Felicetti, S. Oberfield, J. Chanoine, F. Chiarelli, P. Clayton, W. Cutfield
{"title":"Endocrine and Metabolic Late Effects in Cancer Survivors","authors":"Francesco Felicett, E. Brignardello, H. Santen, F. Felicetti, S. Oberfield, J. Chanoine, F. Chiarelli, P. Clayton, W. Cutfield","doi":"10.1159/isbn.978-3-318-06791-0","DOIUrl":"https://doi.org/10.1159/isbn.978-3-318-06791-0","url":null,"abstract":"Subjects: Neoplasms--drug therapy | Antineoplastic Agents--adverse effects | Endocrine Glands--drug effects | Endocrine System Diseases--chemically induced Metabolic Networks and Pathways--drug","PeriodicalId":50428,"journal":{"name":"Frontiers of Hormone Research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43236337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alberto Ragni, Francesca Retta, Emanuela Arvat, Marco Gallo
{"title":"Diabetes in Cancer Patients: Risks, Goals and Management.","authors":"Alberto Ragni, Francesca Retta, Emanuela Arvat, Marco Gallo","doi":"10.1159/000513807","DOIUrl":"https://doi.org/10.1159/000513807","url":null,"abstract":"<p><p>Diabetes mellitus (DM) is commonly found in cancer patients. The relationship between DM and cancer appears to be bidirectional: DM has been associated with an increased risk of developing several types of cancer while also cancer treatments, through the induction of metabolic derangements, can facilitate the onset of DM, or worsen glucose control. In particular, novel antineoplastic treatments such as immunotherapy and targeted therapies have been associated with both acute and long-term metabolic consequences. An adequate management of DM in cancer patients is pivotal, since DM can negatively affect the clinical outcomes of these subjects, being associated with worse survival. However, DM management in cancer patients may be challenging given the peculiarities of these conditions. Lower reliability of HbA1c, a thorough evaluation of the safety profile of antidiabetic drugs, and the need to adapt glycemic targets to patients' prognosis should be taken into consideration. Moreover, DM is commonly encountered also in the ever-growing population of cancer survivors, contributing to their increased cardiovascular risk. In conclusion, taking in consideration the lack of specific guidelines, the particular features of the condition, and the potential impact on prognosis, a multidisciplinary management of DM in cancer patients and survivors is warranted.</p>","PeriodicalId":50428,"journal":{"name":"Frontiers of Hormone Research","volume":"54 ","pages":"103-114"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25345854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
求助内容：
应助结果提醒方式：